Literature DB >> 16365317

Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series.

David J Daniels1, Natalie R Lenard, Chris L Etienne, Ping-Yee Law, Sandra C Roerig, Philip S Portoghese.   

Abstract

Given the mounting evidence for involvement of delta opioid receptors in the tolerance and physical dependence of mu opioid receptor agonists, we have investigated the possible physical interaction between mu and delta opioid receptors by using bivalent ligands. Based on reports of suppression of antinociceptive tolerance by the delta antagonist naltrindole (NTI), bivalent ligands [mu-delta agonist-antagonist (MDAN) series] that contain different length spacers, and pharmacophores derived from NTI and the mu agonist oxymorphone, have been synthesized and evaluated by intracerebroventricular (i.c.v.) administration in the tail-flick test in mice. In acute i.c.v. studies, the bivalent ligands functioned as agonists with potencies ranging from 1.6- to 45-fold greater than morphine. In contrast, the monovalent mu agonist analogues were substantially more potent than the MDAN congeners and were essentially equipotent with one another and oxymorphone. Pretreatment with NTI decreased the ED(50) values for MDAN-19 to a greater degree than for MDAN-16 but had no effect on MDAN-21. Chronic i.c.v. studies revealed that MDAN ligands whose spacer was 16 atoms or longer produced less dependence than either morphine or mu monovalent control MA-19. On the other hand, both physical dependence and tolerance were suppressed at MDAN spacer lengths of 19 atoms or greater. These data suggest that physical interaction between the mu and delta opioid receptors modulates mu-mediated tolerance and dependence. Because MDAN-21 was found to be 50-fold more potent than morphine by the i.v. route (i.v.), it offers a previously uncharacterized approach for the development of analgesics devoid of tolerance and dependence.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16365317      PMCID: PMC1323165          DOI: 10.1073/pnas.0506627102

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  38 in total

1.  From models to molecules: opioid receptor dimers, bivalent ligands, and selective opioid receptor probes.

Authors:  P S Portoghese
Journal:  J Med Chem       Date:  2001-07-05       Impact factor: 7.446

2.  A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers.

Authors:  Rashmi G Bhushan; Shiv K Sharma; Zhihua Xie; David J Daniels; Philip S Portoghese
Journal:  J Med Chem       Date:  2004-06-03       Impact factor: 7.446

3.  A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia.

Authors:  Ivone Gomes; Achla Gupta; Julija Filipovska; Hazel H Szeto; John E Pintar; Lakshmi A Devi
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-24       Impact factor: 11.205

4.  Simultaneous quantitative assessment of morphine tolerance and physical dependence.

Authors:  E L Way; H H Loh; F H Shen
Journal:  J Pharmacol Exp Ther       Date:  1969-05       Impact factor: 4.030

5.  Increased biological activity of dimers of oxymorphone and enkephalin: possible role of receptor crosslinking.

Authors:  E Hazum; K J Chang; H J Leighton; O W Lever; P Cuatrecasas
Journal:  Biochem Biophys Res Commun       Date:  1982-01-15       Impact factor: 3.575

6.  Dimeric tetrapeptide enkephalins display extraordinary selectivity for the delta opiate receptor.

Authors:  Y Shimohigashi; T Costa; H C Chen; D Rodbard
Journal:  Nature       Date:  1982-05-27       Impact factor: 49.962

7.  Opiate receptor binding studies in the mouse vas deferens exhibiting tolerance without dependence.

Authors:  P Rubini; R Schulz; M Wüster; A Herz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-05       Impact factor: 3.000

8.  Mu and delta receptors: their role in analgesia in the differential effects of opioid peptides on analgesia.

Authors:  J L Vaught; R B Rothman; T C Westfall
Journal:  Life Sci       Date:  1982-04-26       Impact factor: 5.037

9.  Narcotic antagonistic potency of bivalent ligands which contain beta-naltrexamine. Evidence for bridging between proximal recognition sites.

Authors:  M Erez; A E Takemori; P S Portoghese
Journal:  J Med Chem       Date:  1982-07       Impact factor: 7.446

10.  Differential effects of leucine and methionine enkephalin on morphine-induced analgesia, acute tolerance and dependence.

Authors:  J L Vaught; A E Takemori
Journal:  J Pharmacol Exp Ther       Date:  1979-01       Impact factor: 4.030

View more
  130 in total

1.  Bifunctional μ/δ opioid peptides: variation of the type and length of the linker connecting the two components.

Authors:  Jinguo Ding; Carole Lemieux; Nga N Chung; Peter W Schiller
Journal:  Chem Biol Drug Des       Date:  2012-01-04       Impact factor: 2.817

2.  Naloxone can act as an analgesic agent without measurable chronic side effects in mice with a mutant mu-opioid receptor expressed in different sites of pain pathway.

Authors:  Shu-Husan Chou; Jen-Hsin Kao; Pao-Luh Tao; Ping-Yee Law; Horace H Loh
Journal:  Synapse       Date:  2012-03-31       Impact factor: 2.562

Review 3.  Drug discovery research targeting the CXC chemokine receptor 4 (CXCR4).

Authors:  Won-Tak Choi; Srinivas Duggineni; Yan Xu; Ziwei Huang; Jing An
Journal:  J Med Chem       Date:  2011-12-02       Impact factor: 7.446

Review 4.  On the expanding terminology in the GPCR field: the meaning of receptor mosaics and receptor heteromers.

Authors:  Luigi F Agnati; Diego Guidolin; Jean Pierre Vilardaga; Francisco Ciruela; Kjell Fuxe
Journal:  J Recept Signal Transduct Res       Date:  2010-10       Impact factor: 2.092

Review 5.  Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes.

Authors:  Nicola J Smith; Graeme Milligan
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

6.  Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.

Authors:  Lauren C Purington; Katarzyna Sobczyk-Kojiro; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  ACS Chem Biol       Date:  2011-10-11       Impact factor: 5.100

7.  Cross-receptor interactions between dopamine D2L and neurotensin NTS1 receptors modulate binding affinities of dopaminergics.

Authors:  Susanne Koschatzky; Nuska Tschammer; Peter Gmeiner
Journal:  ACS Chem Neurosci       Date:  2011-04-11       Impact factor: 4.418

8.  Delta-opioid receptor antagonists prevent sensitization to the conditioned rewarding effects of morphine.

Authors:  Toni S Shippenberg; Vladimir I Chefer; Alexis C Thompson
Journal:  Biol Psychiatry       Date:  2008-10-31       Impact factor: 13.382

9.  Tuned-Affinity Bivalent Ligands for the Characterization of Opioid Receptor Heteromers.

Authors:  Jessica H Harvey; Darcie H Long; Pamela M England; Jennifer L Whistler
Journal:  ACS Med Chem Lett       Date:  2012-08-09       Impact factor: 4.345

10.  Modulation of opiate-related signaling molecules in morphine-dependent conditioned behavior: conditioned place preference to morphine induces CREB phosphorylation.

Authors:  José A Morón; Srinivas Gullapalli; Chirisse Taylor; Achla Gupta; Ivone Gomes; Lakshmi A Devi
Journal:  Neuropsychopharmacology       Date:  2009-12-02       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.